DK3003343T3 - Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme - Google Patents

Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme Download PDF

Info

Publication number
DK3003343T3
DK3003343T3 DK14807179.8T DK14807179T DK3003343T3 DK 3003343 T3 DK3003343 T3 DK 3003343T3 DK 14807179 T DK14807179 T DK 14807179T DK 3003343 T3 DK3003343 T3 DK 3003343T3
Authority
DK
Denmark
Prior art keywords
lymphangiogenese
angiogenese
peptid
biomimetic
treatment
Prior art date
Application number
DK14807179.8T
Other languages
Danish (da)
English (en)
Inventor
Aleksander S Popel
Niranjan B Pandey
Jordan J Green
Ron B Shmueli
Esak Lee
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of DK3003343T3 publication Critical patent/DK3003343T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
DK14807179.8T 2013-06-07 2014-06-09 Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme DK3003343T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361832290P 2013-06-07 2013-06-07
PCT/US2014/041526 WO2014197892A1 (en) 2013-06-07 2014-06-09 A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases

Publications (1)

Publication Number Publication Date
DK3003343T3 true DK3003343T3 (da) 2020-02-03

Family

ID=52008639

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14807179.8T DK3003343T3 (da) 2013-06-07 2014-06-09 Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme

Country Status (11)

Country Link
US (4) US9802984B2 (enExample)
EP (2) EP3643318A1 (enExample)
JP (2) JP6470740B2 (enExample)
CN (2) CN105431162B (enExample)
AU (1) AU2014274703B2 (enExample)
CA (1) CA2914764C (enExample)
DK (1) DK3003343T3 (enExample)
ES (1) ES2774217T3 (enExample)
HU (1) HUE047735T2 (enExample)
IL (1) IL242760B (enExample)
WO (1) WO2014197892A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3003343T3 (da) * 2013-06-07 2020-02-03 Univ Johns Hopkins Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme
WO2016022947A1 (en) 2014-08-07 2016-02-11 The Johns Hopkins University Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
CN108883150A (zh) * 2015-11-19 2018-11-23 阿斯克雷佩西治疗公司 具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂
JP2019535651A (ja) * 2016-10-04 2019-12-12 アスクレピクス セラピューティクス インコーポレイテッド Tie2シグナル伝達を活性化するための化合物及び方法
WO2018208829A1 (en) * 2017-05-08 2018-11-15 Asclepix Therapeutics, Llc Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
EP3661536A4 (en) * 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. PROCESSES FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE THE TIE2 RECEPTOR
WO2019075056A1 (en) 2017-10-10 2019-04-18 The Johns Hopkins University BIODEGRADABLE BIOMIMETIC PARTICLES
US11697804B2 (en) 2018-10-01 2023-07-11 The Johns Hopkins University Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy
CN113507925A (zh) * 2019-02-06 2021-10-15 北卡罗来纳大学教堂山分校 用于抑制术后粘连的组合物和方法
KR20210146352A (ko) * 2019-03-26 2021-12-03 아스클리픽스 테라퓨틱스, 인크. 안구 질환 치료용 조성물 및 방법
CN113144213B (zh) * 2021-03-23 2023-04-07 西安交通大学医学院第一附属医院 一种多级pH响应基因-药物共递送的纳米药物、制备方法及其应用
WO2024044745A2 (en) * 2022-08-26 2024-02-29 Asclepix Therapeutics, Inc. Formulations for intraocular delivery of peptides derived from type iv collagen

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009512423A (ja) 2005-09-12 2009-03-26 ザ・ジョンズ・ホプキンス・ユニバーシティ 抗血管新生の活性を有する組成物及びその使用
WO2007120368A2 (en) * 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
ITMI20060625A1 (it) * 2006-03-31 2007-10-01 Istituto Naz Per La Ricerca Peptide antiangiogenico e suoi impieghi terapeutici
WO2008063932A2 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
US8507434B2 (en) * 2007-01-03 2013-08-13 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
CN102083423A (zh) * 2008-05-06 2011-06-01 葛兰素集团有限公司 生物活性剂的囊封方法
AU2009275135A1 (en) 2008-07-21 2010-01-28 Compugen Ltd. Angiopoietin derived peptides
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
US20130017265A1 (en) 2009-12-16 2013-01-17 Massachusetts Institute Of Technology Particles for multiple agent delivery
US20120192339A1 (en) 2010-07-28 2012-08-02 Honeywell International Inc. Flexible Body Armor Vest with Breast Plate
US20120270770A1 (en) * 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses
US9056923B2 (en) * 2010-12-10 2015-06-16 The Johns Hopkins University Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphagiogenesis-dependent diseases
CN103547639B (zh) 2011-02-24 2016-08-17 柯尼卡美能达株式会社 活性光线固化型喷墨油墨及图像形成方法
WO2014066811A1 (en) 2012-10-25 2014-05-01 The Johns Hopkins University Bioreducible poly (b-amino ester)s for sirna delivery
WO2014066898A1 (en) 2012-10-26 2014-05-01 The Johns Hopkins University A layer-by-layer approach to co-deliver dna and sirna via aunps: a potential platform for modifying release kinetics
DK3003343T3 (da) * 2013-06-07 2020-02-03 Univ Johns Hopkins Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme

Also Published As

Publication number Publication date
CN110981941A (zh) 2020-04-10
JP6931011B2 (ja) 2021-09-01
CN105431162A (zh) 2016-03-23
US20200361993A1 (en) 2020-11-19
US11981754B2 (en) 2024-05-14
IL242760B (en) 2021-03-25
CA2914764C (en) 2021-10-26
EP3003343A1 (en) 2016-04-13
HK1222542A1 (zh) 2017-07-07
AU2014274703B2 (en) 2019-07-04
CA2914764A1 (en) 2014-12-11
EP3003343B1 (en) 2019-10-23
WO2014197892A1 (en) 2014-12-11
EP3643318A1 (en) 2020-04-29
AU2014274703A1 (en) 2015-12-10
ES2774217T3 (es) 2020-07-17
US20240391957A1 (en) 2024-11-28
US20180134753A1 (en) 2018-05-17
JP2016521712A (ja) 2016-07-25
US20160122390A1 (en) 2016-05-05
US9802984B2 (en) 2017-10-31
US10774112B2 (en) 2020-09-15
JP6470740B2 (ja) 2019-02-13
HUE047735T2 (hu) 2020-05-28
CN105431162B (zh) 2019-12-10
JP2019089790A (ja) 2019-06-13
EP3003343A4 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
DK3003343T3 (da) Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme
IL248730A0 (en) Drug delivery system and method of use
DK3234107T3 (da) B-celler til in vivo-levering af terapeutiske midler
DK3350157T3 (da) Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
DK3328414T3 (da) Sammensætning til anvendelse i fremme af sårheling
DK3035955T3 (da) Sammensætning og vaccine til behandling af lungekræft
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3450553T3 (da) Mrna-terapi til behandling af øjensygdomme
DK3209681T3 (da) Farmaceutiske sammensætninger omfattende peptidvarianter og fremgangsmåder til anvendelse deraf
IL252172A0 (en) Expandable drug delivery devices and method of use
DK3204095T3 (da) Inhalationsindretning til anvendelse i aerosolbehandling af luftsvejssygdomme
DK3692857T3 (da) Indretning til levering af hudplejesammensætning
HRP20181269T1 (hr) Peptidi i sastavi za liječenje oštećenja zglobova
DK3041926T3 (da) Indretning til in-vitro-modellering af in-vivo-væv af organer
PL3362084T3 (pl) Urządzenia do podawania dojelitowego i powiązane sposoby zastosowania
DK3351239T3 (da) Prostamid-indeholdende intraokulære implantater og fremgangsmåder til anvendelse deraf
DK3049117T3 (da) Ultralydsmedieret afgivelse af lægemidler
EP3212170C0 (en) IMPLANTABLE MEDICAL DEVICES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS
DK3828203T3 (da) Sammensætninger og fremgangsmåder til behandling af fedtvævsopbygning
DK3113782T3 (da) Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin
DK2890384T3 (da) Lægemiddelleveringsystemer og fremgangsmåder til behandling af blærekræft omfattende oxaliplatin
PL3204030T3 (pl) Terapia skojarzona zakażenia hbv i hdv
DK3164394T3 (da) Gls1-inhibitorer til behandling af sygdomme
FI20146023A7 (fi) Hammas- ja kielituki
DK3237621T5 (da) Varianter af human alpha-galactosidase